Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors’’ dose requirements and trough blood levels in stable renal transplant patients

By Elens Laure   van Schaik Ron H   Panin Nadtha   de Meyer Martine   Wallemacq Pierre   Lison Dominique   Mourad Michel   Haufroid Vincent  

Pharmacogenomics, Vol. 12, Iss. 10, 2011-10 ,pp. : 1383-1396

Future Medicine

Access to resources Recommend Favorite

Impact of CYP3A5 genotype on tacrolimus versus midazolam clearance in renal transplant recipients: new insights in CYP3A5-mediated drug metabolism

By de Jonge Hylke   de Loor Henriette   Verbeke Krisitin   Vanrenterghem Yves   Kuypers Dirk RJ  

Pharmacogenomics, Vol. 14, Iss. 12, 2013-09 ,pp. : 1467-1480

Future Medicine

Access to resources Recommend Favorite

Influence of Cytochrome P450 (CYP) 3A5 Polymorphisms on the Pharmacokinetics of Lansoprazole Enantiomers in CYP2C19 Extensive Metaboliser Renal Transplant Recipients

By Miura Masatomo  

Clinical Drug Investigation, Vol. 27, Iss. 4, 2007-01 ,pp. : 251-258

Adis International

Access to resources Recommend Favorite

Using genetic and clinical factors to predict tacrolimus dose in renal transplant recipients

By Wang Ping   Mao Yong   Razo Juan   Zhou Xiaobo   Wong Stephen TC   Patel Samir   Elliott Erin   Shea Erin   Wu Alan HB   Gaber A Osama  

Pharmacogenomics, Vol. 11, Iss. 10, 2010-10 ,pp. : 1389-1402

Future Medicine

Access to resources Recommend Favorite

The P450 oxidoreductase *28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients

By de Jonge Hylke   Metalidis Christoph   Naesens Maarten   Lambrechts Diether   Kuypers Dirk RJ  

Pharmacogenomics, Vol. 12, Iss. 9, 2011-09 ,pp. : 1281-1291

Future Medicine

Access to resources Recommend Favorite